Abstract
Girls with Turner's Syndrome (TS) were treated with three different regimens: a) Oxandrolone (Oxa) 0.1 mg/kg/day, b) recombinant human growth hormone (rhGH) 28 U/m2/week and c) rhGH 24 U/m2/week with Oxa 0.06 mg/kg/day (mGH+Oxa). Growth data are presented for the first two years of treatment. None of the girls were given any estrogens. Bone age (BA) was assessed by the TW2-RUS method and expressed in Turner specific bone age (BATS) based on the mean BA data for untreated TS (1). Therefore, in contrast to using BA deriving from non affected girls, the increase in BATS in untreated TS is by definition 1 year/ year at any age.
In all three treatment regimens, the increase in BATS is more pronounced the younger the girls are at onset of treatment. Δ Height SDS for BATS, as an index of the gain in final height, is less in girls younger than 8 yrs at the beginning of the treatment.
Conclusion: 1) There is no benefit of any growth promoting treatment in girls with TS before the age of 8 yrs. 2) Adding a small dose of Oxa to rhGH the same increase in predicted final height (Δ Height SDS for BATS) is achieved in a shorter time.
1) Ranke M. et al. Eur.J Pediatr 1983:141:81-88.
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Partsch, C., Joss, E., Mullis, P. et al. TURNER'S SYNDROME: EFFECT OF GROWTH HORMONE AND/OR OXANDROLONE ON HEIGHT VELOCITY AND TURNER SPECIFIC BONE AGE TAKING THE AGE OF ONSET OF TREATMENT INTO ACCOUNT. Pediatr Res 33 (Suppl 5), S55 (1993). https://doi.org/10.1203/00006450-199305001-00310
Issue date:
DOI: https://doi.org/10.1203/00006450-199305001-00310
